Citadel Advisors’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-33,600
| Closed | -$316K | – | 11862 |
|
|
2020
Q3 | $316K | Buy |
33,600
+21,300
| +173% | +$202K | ﹤0.01% | 8048 |
|
|
2020
Q2 | $94K | Sell |
12,300
-1,100
| -8% | -$8.42K | ﹤0.01% | 9026 |
|
|
2020
Q1 | $83K | Sell |
13,400
-52,900
| -80% | -$466K | ﹤0.01% | 8758 |
|
|
2019
Q4 | $807K | Buy |
66,300
+22,500
| +51% | +$246K | ﹤0.01% | 5981 |
|
|
2019
Q3 | $506K | Sell |
43,800
-15,700
| -26% | -$165K | ﹤0.01% | 6731 |
|
|
2019
Q2 | $594K | Buy |
59,500
+19,100
| +47% | +$206K | ﹤0.01% | 6564 |
|
|
2019
Q1 | $520K | Buy |
40,400
+26,300
| +187% | +$392K | ﹤0.01% | 6728 |
|
|
2018
Q4 | $214K | Hold |
14,100
| – | – | ﹤0.01% | 7772 |
|
|
2018
Q3 | $282K | Sell |
14,100
-2,600
| -16% | -$59.2K | ﹤0.01% | 7673 |
|
|
2018
Q2 | $326K | Sell |
16,700
-21,700
| -57% | -$480K | ﹤0.01% | 7074 |
|
|
2018
Q1 | $774K | Buy |
38,400
+11,900
| +45% | +$201K | ﹤0.01% | 5199 |
|
|
2017
Q4 | $351K | Buy |
26,500
+1,700
| +7% | +$25.6K | ﹤0.01% | 6197 |
|
|
2017
Q3 | $458K | Buy |
24,800
+5,800
| +31% | +$108K | ﹤0.01% | 5465 |
|
|
2017
Q2 | $350K | Buy |
19,000
+5,200
| +38% | +$103K | ﹤0.01% | 5653 |
|
|
2017
Q1 | $311K | Buy |
13,800
+2,400
| +21% | +$57.5K | ﹤0.01% | 5843 |
|
|
2016
Q4 | $397K | Sell |
11,400
-8,400
| -42% | -$251K | ﹤0.01% | 5267 |
|
|
2016
Q3 | $485K | Sell |
19,800
-23,400
| -54% | -$585K | ﹤0.01% | 4909 |
|
|
2016
Q2 | $1.03M | Sell |
43,200
-10,400
| -19% | -$238K | ﹤0.01% | 3510 |
|
|
2016
Q1 | $1.25M | Buy |
53,600
+23,600
| +79% | +$560K | ﹤0.01% | 3203 |
|
|
2015
Q4 | $906K | Buy |
30,000
+8,900
| +42% | +$288K | ﹤0.01% | 3697 |
|
|
2015
Q3 | $838K | Buy |
21,100
+8,200
| +64% | +$509K | ﹤0.01% | 4053 |
|
|
2015
Q2 | $891K | Buy |
12,900
+6,700
| +108% | +$422K | ﹤0.01% | 4115 |
|
|
2015
Q1 | $339K | Buy |
6,200
+4,400
| +244% | +$210K | ﹤0.01% | 5478 |
|
|
2014
Q4 | $77K | Buy |
1,800
+600
| +50% | +$21.7K | ﹤0.01% | 6875 |
|
|
2014
Q3 | $38K | Buy |
1,200
+800
| +200% | +$17.1K | ﹤0.01% | 7089 |
|
|
2014
Q2 | $8K | Sell |
400
-5,000
| -93% | -$92.4K | ﹤0.01% | 7637 |
|
|
2014
Q1 | $104K | Buy |
5,400
+100
| +2% | +$2.12K | ﹤0.01% | 6165 |
|
|
2013
Q4 | $129K | Sell |
5,300
-1,200
| -18% | -$28.2K | ﹤0.01% | 5409 |
|
|
2013
Q3 | $140K | Buy |
6,500
+800
| +14% | +$18.9K | ﹤0.01% | 5076 |
|
|
2013
Q2 | $127K | Buy |
+5,700
| New | +$126K | ﹤0.01% | 5043 |
|
Citadel Advisors's AMAG Position: Q4 2020 in Review
Citadel Advisors sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 134,552 shares — an estimated $1.26M sold.
Citadel Advisors first reported a position in AMAG in Q2 2013 and held it in 25 quarters. The position peaked at $21.4M in Q2 2017. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Citadel Advisors reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Citadel Advisors sold 134,552 AMAG Pharmaceuticals shares in Q4 2020, an estimated $1.26M.
- Citadel Advisors first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 25 quarters.
- Citadel Advisors's AMAG Pharmaceuticals position peaked at $21.4M in Q2 2017.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.